ストックスクリーナーアプリを入手
0.9481
11.57%
-0.1219
前日終値:
$1.07
開ける：
$0.9889
24時間の取引高:
1.57M
Relative Volume:
1.43
時価総額：
$94.81M
収益：
$1.63M
当期純損益:
$-40.95M
株価収益率:
-1.6154
EPS:
-0.5869
ネットキャッシュフロー:
$-18.80M
1週間 パフォーマンス:
+6.99%
1か月 パフォーマンス:
+0.78%
6か月 パフォーマンス:
-41.59%
1年 パフォーマンス:
+53.40%
1日の値動き範囲:
$0.92
$0.9894
1週間の範囲:
$0.8901
$1.12
52週間の値動き範囲:
$0.387
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
名前
Rani Therapeutics Holdings Inc
セクター
電話
(408) 457-3700
住所
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.9489 | 106.91M | 1.63M | -40.95M | -18.80M | -0.5869 |
VRTX
Vertex Pharmaceuticals Inc
|
436.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
636.71 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.12 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.55 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.84 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-14 | 開始されました | Lake Street | Buy |
| 2024-08-02 | 開始されました | Oppenheimer | Outperform |
| 2024-06-14 | 開始されました | Maxim Group | Buy |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-04-17 | 再開されました | BTIG Research | Buy |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-07-27 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-13 | 開始されました | Wedbush | Outperform |
すべてを表示
Rani Therapeutics Holdings Inc (RANI) 最新ニュース
Rani Therapeutics raises $20 million in direct offering - Investing.com
Rani Therapeutics to raise $20M in registered direct offering - MSN
Sovereign wealth fund leads $20M raise for oral drug delivery firm - Stock Titan
Rani Therapeutics Holdings (RANI) price target decreased by 12.50% to 7.14 - MSN
CCORF Maintains Rani Therapeutics(RANI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Rani Therapeutics Price Target Maintained With a $5.00/Share by Canaccord Genuity - Moomoo
Rani Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
RANI Maintained by Canaccord Genuity -- Price Target Stays at $5 - GuruFocus
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target - Investing.com
Canaccord reiterates Buy on Rani Therapeutics stock, $5 target By Investing.com - Investing.com Canada
Insiders Enjoy US$582k Return After Buying Rani Therapeutics Holdings Stock - simplywall.st
Lake Street Initiates Rani Therapeutics(RANI.US) With Buy Rating, Announces Target Price $9 - Moomoo
Rani Therapeutics CFO Sanford to depart - MSN
Nasdaq Delisting Risk Looms as Rani Therapeutics Fails to Meet $1 Minimum Bid Price - TipRanks
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition - The Manila Times
Rani Therapeutics Q1 Net Loss Narrows, Revenue Rises; CFO Svai Sanford to Step Down - Moomoo
RANI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Rani Therapeutics reports Q1 EPS (4c), consensus (5c) - TipRanks
Rani Therapeutics Sees Funding Sufficient Into 4Q27 >RANI - Moomoo
Rani Therapeutics CFO to depart, reports Q1 results - Investing.com UK
Rani Therapeutics CFO to depart, reports Q1 results By Investing.com - Investing.com South Africa
Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice - TipRanks
Rani Therapeutics Holdings Inc reports results for the quarter ended March 31Earnings Summary - TradingView
RANI: Q1 2026 saw clinical progress, leadership changes, and a reduced net loss year-over-year - TradingView
Rani Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Rani Therapeutics (RANI) posts Q1 2026 loss with new Chugai revenue and $43M cash - Stock Titan
Nasdaq warns Rani Therapeutics (NASDAQ: RANI) as CFO plans transition - Stock Titan
Oral biologics firm Rani trims Q1 loss; CFO to step down - Stock Titan
Rani Therapeutics Reports First Quarter 2026 Financial - GlobeNewswire
SymBiosis Capital holds 4.43M RANI shares, reports 4.4% stake (RANI) - Stock Titan
TradingKey - TradingKey
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference - The Manila Times
Rani Therapeutics (NASDAQ:RANI) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Rani Therapeutics Holdings Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
This Rani Therapeutics Holdings Insider Increased Their Holding By 9,754% Last Year - Yahoo Finance
MSN Money - MSN
Rani Therapeutics (RANI) Projected to Post Earnings on Wednesday - MarketBeat
RANI Technical Analysis | Trend, Signals & Chart Patterns | RANI THERAPEUTICS HOLDINGS-A (NASDAQ:RANI) - ChartMill
RANI Price Today: Rani Therapeutics Holdings, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Rani Therapeutics | SCHEDULE 13G: Others - Moomoo
Vanguard Capital Management takes 5.12% stake in Rani Therapeutics (RANI) - Stock Titan
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Rani Therapeutics Holdings (RANI) price target decreased by 13.51% to 8.16 - MSN
Form DEF 14AOther definitive proxy statements - ADVFN
Rani Therapeutics Holdings Inc (RANI) 財務データ
収益
当期純利益
現金流量
EPS
Rani Therapeutics Holdings Inc (RANI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| South Cone Investments Limited | 10% Owner |
Oct 21 '25 |
Sale |
2.77 |
4,000,000 |
11,074,000 |
2,379,194 |
| South Cone Investments Limited | 10% Owner |
Oct 20 '25 |
Sale |
2.41 |
1,923,000 |
4,637,314 |
6,379,194 |
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):